Alexander Hempelmann | Group Leader Biochemistry & Cellbiology
Heidelberg Pharma research GmbH

Dr. Alexander Hempelmann is a German structural biochemist specializing in antibody engineering and protein interactions. He currently serves as a Group Leader for ADC Technologies at Heidelberg Pharma in Ladenburg, Germany, where he focuses on advancing antibody-drug conjugate (ADC) platforms. His academic journey includes a Master of Science degree in Biochemistry from Heidelberg University and prior studies at the University of Göttingen (B.Sc. Biochemistry). He has completed his Ph.D. at the German Cancer Research Center (DKFZ) in Heidelberg, contributing to the Division of Structural Biology of Infection and Immunity. His work in the academic field includes studies on immune epitope mapping using nanobodies and COVID-19 diagnostics. His research focusses on protein engineering and purification and applied X-ray crystallography and cryoEM. His career reflects a commitment to advancing therapeutic strategies through structural biochemistry and innovative diagnostic solutions.